Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCS in BPH-LUTS
NCT00501371Phase 3Terminated
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
- Start
- Jul 2007
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of MCS-2 in benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) (4 arms), sponsored by Health Ever Bio-Tech Co., Ltd. Primary endpoints: Change in International Prostate Symptom Score at 12 weeks and Percentage of subjects achieving I-PSS reduction >= 4 points at 12 weeks. Started Jul 2007; status: terminated.
02
Drugs
MCS-2
03
Conditions
benign prostatic hyperplasia (BPH)lower urinary tract symptoms (LUTS)
Beyond the preview
Go deeper on NCT00501371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00501371.